000076034 001__ 76034
000076034 005__ 20190709135453.0
000076034 0247_ $$2doi$$a10.1016/j.maturitas.2017.04.001
000076034 0248_ $$2sideral$$a98967
000076034 037__ $$aART-2017-98967
000076034 041__ $$aeng
000076034 100__ $$0(orcid)0000-0002-2801-416X$$aPerez-Lopez, F.R.$$uUniversidad de Zaragoza
000076034 245__ $$aSystematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus
000076034 260__ $$c2017
000076034 5060_ $$aAccess copy available to the general public$$fUnrestricted
000076034 5203_ $$aBackground
Obesity, insulin resistance and type 2 diabetes mellitus (T2DM) have been associated with endometrial cancer (EC). In this systematic review and meta-analysis we evaluated the effect of metformin on clinical outcomes in patients with EC and insulin resistance or T2DM.
Methods
Four research databases were searched for original articles published in all languages up to 30 October 2016. Outcomes of interest were overall mortality (OM), cancer-specific mortality, disease progression, and metastases. We performed a random effect meta-analysis of adjusted effects expressed as hazard ratios (HR); heterogeneity among studies was described with the I2 statistic.
Results
Of the 290 retrieved citations, 6 retrospective cohort studies in women with EC (n = 4723) met the inclusion criteria, and 8.9% to 23.8% were treated with metformin; OM data was available from 5 studies. In 4 studies of EC patients (n = 4132), metformin use was associated with a significant reduction in OM in comparison with not using metformin (adjusted HR [aHR] 0.64, 95% CI 0.45–0.89, p = 0.009). In three studies evaluating patients with EC and T2DM (n = 2637), metformin use was associated with a significant reduction in OM (aHR 0.50, 95%CI 0.34–0.74, p = 0.0006). There was low to moderate heterogeneity of adjusted effects across studies. There was no information about the effect of metformin on cancer-specific mortality, disease progression, or metastases.
Conclusions
Metformin treatment is associated with a significant reduction in OM irrespective of diabetes status in patients with EC. The survival benefit suggests that diabetes screening and maintenance of good glycemic control may improve outcomes in EC.
000076034 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000076034 590__ $$a3.315$$b2017
000076034 591__ $$aOBSTETRICS & GYNECOLOGY$$b12 / 81 = 0.148$$c2017$$dQ1$$eT1
000076034 591__ $$aGERIATRICS & GERONTOLOGY$$b18 / 53 = 0.34$$c2017$$dQ2$$eT2
000076034 592__ $$a1.061$$b2017
000076034 593__ $$aObstetrics and Gynecology$$c2017$$dQ1
000076034 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2017$$dQ1
000076034 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/acceptedVersion
000076034 700__ $$aPasupuleti, V.
000076034 700__ $$aGianuzzi, X.
000076034 700__ $$aPalma-Ardiles, G.
000076034 700__ $$aHernandez-Fernandez, W.
000076034 700__ $$aHernandez, A.V.
000076034 7102_ $$11004$$2645$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Obstetricia y Ginecología
000076034 773__ $$g101 (2017), 6-11$$pMaturitas$$tMaturitas$$x0378-5122
000076034 8564_ $$s551138$$uhttps://zaguan.unizar.es/record/76034/files/texto_completo.pdf$$yPostprint
000076034 8564_ $$s53007$$uhttps://zaguan.unizar.es/record/76034/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000076034 909CO $$ooai:zaguan.unizar.es:76034$$particulos$$pdriver
000076034 951__ $$a2019-07-09-11:42:00
000076034 980__ $$aARTICLE